CA: MRI may do more harm than good in newly diagnosed breast cancer

Using MRI before surgery to assess the extent of early breast cancer has not been shown to improve surgical planning, reduce follow-up surgery or reduce the risk of local recurrences. A review, appearing Aug. 13 online in CA: A Cancer Journal for Clinicians, says evidence shows that MRI utilization increases the chances of more extensive surgery over conservative approaches, with no evidence that it improves surgical care or prognosis.

Randomized controlled trials have shown women with early-stage breast cancer who are treated with breast-conservation therapy (local excision and radiotherapy) have the same survival rates as those who undergo mastectomy, according to the authors. Recently, MRI has been introduced in preoperative staging of the affected breast in women with newly diagnosed breast cancer because it detects additional areas of cancer that do not show up on conventional imaging.

In the current review, Nehmat Houssami, PhD, of the University of Sydney in Australia, and Daniel F. Hayes, MD, of University of Michigan Comprehensive Cancer Center in Ann Arbor, Mich., reviewed available data on the detection capability of preoperative MRI and its impact on treatment.

They found that the use of preoperative MRI scans in women with early-stage breast cancer has been based on assumptions that the detection capability of MRI in this setting will improve surgical planning, potentially leading to a reduction in re-excision surgery, and by guiding surgeons to remove additional disease detected by MRI and potentially reducing recurrence in the treated breast.

The researchers wrote that emerging data show that this approach to local staging of the breast leads to more women being treated with mastectomy without evidence of improvement in surgical outcomes or long-term prognosis.

After reviewing the data, the authors concluded that there is evidence that MRI changes surgical management, generally from breast conservation to more radical surgery, but that there is no evidence that it improves surgical treatment or outcomes.

"Overall, there is growing evidence that MRI does not improve surgical care, and it could be argued that it has a potentially harmful effect," the authors wrote.

Houssami and Hayes said that well-designed, randomized controlled trials are needed to quantify potential benefit and harm, including careful evaluation of its impact on quality of life.

"We acknowledge that logistics and costs of conducting such large-scale, multicenter trials are enormous,” they concluded. “If the technology is truly as beneficial as its proponents claim, then these costs are worth it. If it is not, then they are outweighed by the costs of adopting expensive technology and associated intervention without evidence of clinical benefit.”

Around the web

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”

FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."

With generative AI coming into its own, AI regulators must avoid relying too much on principles of risk management—and not enough on those of uncertainty management.

Trimed Popup
Trimed Popup